RE:San Diego, CTAD, December 5th, 4:00 pm PSTPlus Dr. Winblad and Dr. Zetterberg are chairing and presenting, respectively, in that same symposium. Those two, as well as Dr. Cummings are on the Resverlogix neurodegenerative clinical and scientific advisory board. Add in Resverlogix's Dr. Kulikowski presentation during that session and you have a dominant presence of Resverlogix during that session. Biogen may get the early CTAD headlines with their presentation of Phase 3 aducanumab results to start Thursday December 5, but come the 4 PM Resverlogix session same day at CTAD, we'll see who has bragging rights. BDAZ